Risk Factors | Alzheimer's Prevention Registry

You are here

Home

Risk Factors

Groundbreaking prevention study will positively impact future Alzheimer’s research

At the Alzheimer’s Association International Conference in August 2022, the precedent-setting Alzheimer’s Prevention Initiative study based in Colombia reported the study drug did not slow cognitive decline in participants with a rare genetic mutation that causes early onset Alzheimer’s disease. Learn more about how the outcome of this study will help guide future studies.

How are autism and Alzheimer’s related?

Recent studies suggest a link between Alzheimer’s disease and autism spectrum disorder. Scientists are asking the question: As children diagnosed with autism age into adulthood, how will their diagnosis impact their memory and thinking skills? With hundreds of thousands of elderly adults diagnosed with autism by 2030, now is the time to study this potential association.

Report: Sustaining healthy brain behaviors requires individual and community commitment

In its annual report, the Global Council on Brain Health and AARP brought together experts from around the world to discuss how society can do more to promote activities to support healthy brains as we age. Read what they have to say about how individuals and communities can motivate people to maintain brain-healthy lifestyles. 

New project launches to study Alzheimer’s disease prevention in people with Down syndrome

Approximately 75% of adults with Down syndrome develop Alzheimer’s disease by the age of 65. Researchers are now creating more studies to explore the link between the two and plan to bring the latest therapies into clinical trials for this patient population.

What are clinical trials and how do they work?

New drugs and medical devices are tested for safety and effectiveness in several phases of clinical trials. But how exactly does a clinical trial work? And what is the difference between Phase I and Phase II? This month we explore the inner workings of clinical trials and their role in testing new medical treatments. 

Alzheimer’s Prevention Registry wraps up 2021 and looks to 2022 for new study opportunities

Thank you for your continued support of our mission to end Alzheimer’s disease before losing another generation. As 2021 comes to a close, we are excited about the many new opportunities we foresee next year to participate in groundbreaking prevention research.

Alzheimer’s Disease Awareness Month shines spotlight other dementias

Alzheimer’s disease makes up 60 to 80 percent of all dementias. But what else can cause memory and thinking problems? Learn more about other causes of dementia along with their varied symptoms.

Digital devices and artificial intelligence partner to measure early brain changes

Smartphones and smartwatches already measure our heart rate, sleep patterns and oxygen levels. These and other so-called digital biomarkers coupled with artificial intelligence could one day soon identify early memory and thinking changes to help us optimize our brain health.

Study explores whether computerized brain training can prevent dementia

A new, NIH-funded, multi-site study is exploring whether computerized brain training can prevent dementia. Preventing Alzheimer’s with Cognitive Training (PACT) will examine whether a specific type of computerized training can reduce the risk of dementia such as Alzheimer’s disease for adults over 65.  

New study uses tailored dosing approach that aims to help prevent Alzheimer’s

A new Alzheimer’s clinical trial is recruiting people as young as 55 to participate in a study of an anti-amyloid investigational therapy. The study is groundbreaking because the study medication doses are tailored based on each participant’s level of brain amyloid. Read more about how the AHEAD Study aims to get ahead of Alzheimer’s before symptoms appear.